medigraphic.com
ISSN 1817-5996 (Electronic)

2013, Number 2

<< Back Next >>

Rev Cub de Reu 2013; 15 (2)

Polymyositis-dermatomyositis and pregnancy

Molinero RC, Prada HD, Gómez MJA, Hernández CMV, Hernández CIM, Milera RJ, Rodríguez ZJ, López MAM, Reyes PY, Gil PJ, López VJ, Rodríguez RA

Language: Spanish
References: 53
Page:
PDF size: 160.03 Kb.


ABSTRACT

Polymyositis-dermatomyositis is a diffuse inflammatory disease of skeletal muscle of unknown etiology existing evidence of immunological factors in its pathogenesis .The incidence of the disease is low and involves mainly skin and muscles. It could be an acute, sub-acute and chronic illness which produces atrophy and degeneration of muscles .The idiopathic inflammatory myopathies are well defined considering etiopathogenic factors, therapy and prognosis .However scientific reports do not make important differences between polymyositis and dermatomyositis. References of polymyositis-dermatomyositis and pregnancy are not common probably associated to the low incidence of the disease being the higher prevalence about the fifty years of age.


REFERENCES

  1. Nava Arnulfo, Orozco-Barocio Gerardo. Abordaje en el diagnóstico diferencial de las miopatías inflamatorias. Miopatías inflamatorias. Volumen 05, Número Extra3, Reumatol Clin. 2009; Supl 3(5):32-4.

  2. Hilton-Jones D. Observations on the classification of the inflammatory myopathies. Presse Med. 2011; 40:199-208.

  3. Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009; 80:1060-8.

  4. Berrocal Alfredo, Ramírez Erick, Calvo Armando. El embarazo no exacerba la dermatomiositis Rev Med Hered 10 (3), 1999 125- 128.

  5. Ricardo Y, Villa–Juárez M. Polimiositis/ dermatomiositis y embarazo. Rev. SaludmILITAR Mex. 2002; 56(1): 40 -45.

  6. Mastaglia F.L., Phillips B.A. Idiopathic inflammatory myopathies: Epidemiology, classification, and diagnostic criteria. Rheum Dis Clin North Am. 2002; 28:723-41.

  7. Vargas-Leguás H, Selva-O'Callaghan A, Campins-Martí M, Hermosilla Pérez E, Grau-Junyent JM, Martínez Gómez X, et al. [Polymyositis-dermatomyositis: incidence in Spain (1997-2004)]. Med Clin (Barc). 2007; 129:721-4.

  8. Hoogendijk J.E., Amato A.A., Lecky B.R., Choy E.H., Lundberg I.E., Rose M.R., et-al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004; 14:337-45.

  9. Selva O'Callaghan Albert, Trallero Araguás Ernesto. Miopatías inflamatorias. Dermatomiositis, polimiositis y miositis con cuerpos de inclusión. Revisión. Volumen 4, Número 5, Septiembre 2008.

  10. Christopher-Stinea L, Plotz PH. Myositis: an update on pathogenesis. Curr Opin Rheumatol. 2004;16:700-6.

  11. Okada S, Weatherhead E, Targoff IN, Wesley R, Miller FW, for the International Collaborative Study Group. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune diseases. Arthritis Rheum. 2003;48:2285-93.

  12. Selva-O'Callaghan A, Boeckh-Behrens TM, Balada-Prades E, Solans-Laque R, Vilardell-Tarrés M. Fetal microchimerism and inflammatory myopathies. Lancet. 2001; 357:887-94.

  13. Artlett CM, Ramos R, Jiminez SA, Patterson K, Miller FW, Rider LG. Chimeric cells of maternal origin in juvenile idiopathic inflammatory myopathies. Childhood Myositis Heterogeneity Collaborative Group. Lancet. 2000; 356:2155-6.

  14. Selva-O'Callaghan A, Tura JM, Grau-Junyent JM, Labrador-Horrillo M, Solans-Laque R, Vilardell-Tarrés M. Silicone gel filled breast implants and dermatomyositis. Clin Exp Rheumatol. 2004; 22:376-89.

  15. Caramaschi P, Biasi D, Volpe A, Carletto A, Bambara LM. A new case of dermatomyositis following the rupture of a silicone gel breast implant. Clin Exp Rheumatol. 2005; 23:430-1.

  16. Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R, Simeon-Aznar CP, Martínez-Gómez X, Vilardell-Tarrés M. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum. 2006; 55:791-8.

  17. Hengstman GJ, Ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006; 65:1635-8.

  18. Gunawardena H, Wedderburn LR, North J, Betteridge Z, Dunphy J, Chinoy H, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford). 2008;47:324-8.

  19. FrederickW, MillerMD.Idiopathic inflammatory myopathies.Rheumatic Disease Clinics of North America2002; 4:833-52.

  20. Spencer R. Inflammatory Muscle Disease. In West S (Ed): Rheumatology Secrets. Philadelphia, Hanley & Belfus. 1997:141- 150.

  21. Guzmán J, Petty RE, Malleson PN y cols. Monitoring disease activity in juvenile dermatomyositis: the role of Von Willebrand factor and muscle enzyme. J Rheumatol 1994, 21(4): 739-43.

  22. Bohan A, Peter J, Browman R, et al. A computer analysis of 153 patients with PM/DM. Medicine 1977; 56: 255-86.

  23. Dalakas M.C., Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362:971-82.

  24. Briani C, Doria A, Sarzi-Puttini P, Dalakas M.C. Update on idiopathic inflammatory myopathies. Autoimmunity. 2006; 39:161-70.

  25. Mastaglia F.L. Inflammatory muscle diseases. Neurol India. 2008; 56:263-70.

  26. Gerardo Gutiérrez-Gutiérreza; Carla Barbosa Lópeza; Francisco Navacerradab; Ambrosio Miralles Martíneza Utilidad del electromiograma en el diagnóstico de las miopatías inflamatorias. Revisiones. 2012;08(04).

  27. Kyriakides T, Angelini C, Schaefer J, Sacconi S, Siciliano S, Vilchez JJ, et-al. EFNS guidelines on the diagnostic approach to pauci- or asymptomatic hyperCKemia. Eur J Neurol. 2010; 17:767-73.

  28. Choy EH, Hoogendijk JE, Lecky B, Winer JB. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev. 2005.

  29. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E, et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323-7.

  30. Chung YL, Alexanderson H, Pipitone N, Morrison C, Dastmalchi M, Ståhl-Hallengren C, et al. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;57:694-702.

  31. Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Barbasso Helmers S, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008 Feb 13. 6(4): 45-52.

  32. Selva-O'Callaghan A, Labrador-Horrillo M, Vilardell-Tarres M. Specific biologic therapy with tumor necrosis factor inhibitors in patients with inflammatory myopathy. Curr Rheumatol Rev. 2005;1:157-65.

  33. Guillermo Ruiz-Irastorzaa,b, María José Cuadradob,c y Munther A. Khamashtad Enfermedades autoinmunes sistémicas durante el embarazo: una aproximación práctica Med Clin (Barc) 1998; 111: 785-97.

  34. Gutiérrez G, Dagnino R, Mintz G. Polymyositis/dermatomyositis andpregnancy. Arthritis Rheum 1984; 27: 291-94.

  35. Rosenzweig BA, Rotmensch S, Binette SP, Phillippe M. Primary idiopathic idiopathic polymyositis and dermatomyositis complicating pregnancy: diagnosisand management. Obstet Gynecol Surv 1989; 44: 162-70.

  36. Pinheiro GRC, Goldenberg J, Atra E, Pereira RB, Camano I, Schmidt B.Juvenile dermatomyositis and pregnancy: report and literature review. JRheumatol 1992; 19: 1.798-1.801.

  37. Oros J, Gil B, Risco Cortes R, et al. Miositis y gestación. Ginecol Obstet Mex 1994; 62: 103-06.

  38. Arturo Juárez-Azpilcueta, Gonzalo Pol-Kipes, Gabriela Olivo-Arroyo, Arturo Ortiz-Pavón, Fausto Coronel-Cru Dermatomiositis y embarazo Gac Méd Méx. 2003;139(5): 27-32.

  39. Ishii N, Ono H, Kawaguchi T, Nakajima H. Dermatomyositis in pregnancy. Case report and review of the literature. Dermatologica 1991; 183: 146-49.

  40. Friedman SA, Bernstein MS, Kitzmiller JL. Pregnancy complicated by collagen vascular disease. Obstet Gynecol Clin North Am 1991; 18:213-36.

  41. England MJ, Perlmann T, Veriana Y. Dermatomyositis in pregnancy. Acase report. J Reprod Med 1986; 31: 633-36.

  42. Williams L, Chang PY, Park E. Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy.Obstet Gynecol. 2007;109:561-63.

  43. Harris A, Webley M, Usherwood M, Burge S. Dermatomyositis presenting in pregnancy. Br J Dermatol 1995; 133: 783-85.

  44. Jeffrey P Callen, MD Dermatomyositis Article. Last Updated: Feb 14, 2008; 8(2): 21-45..

  45. Vancsa A, Ponyi A, Constantin T. Pregnancy outcome in idiopathic inflammatory myopathy. Rheumatol Int. 2007;27:435-39.

  46. Park IW, Suh YJ, Han JH, et al. Dermatomyositis developing in the first trimester of pregnancy. Korean J Intern Med. 2003;18:196-198.

  47. Pasrija S, Rana R, Sardana K. A case of autoimmune myopathy in pregnancy. Indian J Med Sci. 2005;59:109-112.

  48. Silva CA, Sultan SM, Isenberg DA. Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. Rheumatology. 2003;42:1168-72.

  49. WolfbergA J, Lee-Parritz A, Peller AJ, Lieberman ES. Association of rheumatologic disease with preeclampsia. Obstet Gynecol. 2004; 103:1190-93.

  50. Juanola Roura X, Ríos Rodríguez V, de la Fuente de Dios D. Fármacos durante el embarazo y métodos contraceptivos en enfermedades reumáticas. Nuevas aportaciones. Revisiones. 2010; 06(01): 28-37.

  51. Ugarte A. Manejo del embarazo en pacientes con lupus eritematoso sistémico. Rev Clin.Esp. 2012;11.(03): 65-72.

  52. Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: tenquestions and some answers. Lupus. 2008;17:416-20.

  53. Seema Chopra, Vanita Suri, Rashmi B Agga, Autoimmune inflammatory Myopathy in Pregnancy Medscape. J Med.2008; 8(4): 53-71.




2020     |     www.medigraphic.com